Evaluating the efficacy and safety of rivaroxaban as a warfarin alternative in chronic thromboembolic pulmonary hypertension patients undergoing pulmonary endarterectomy : A randomized clinical trial
Copyright © 2022 Sociedade Portuguesa de Cardiologia. Publicado por Elsevier España, S.L.U. All rights reserved..
BACKGROUND AND AIM: Chronic thromboembolic pulmonary hypertension (CTEPH) is caused by the obstruction of the main pulmonary artery due to thrombosis and vascular remodeling. Regarding the need for anticoagulant therapy in CTEPH patients, this study aimed to compare rivaroxaban with warfarin in terms of its efficacy and safety in patients undergoing endarterectomy surgery.
METHODS: The study was a parallel clinical trial in patients who underwent endarterectomy following CTEPH. A total of 96 patients were randomly selected and assigned to two groups: warfarin-treated (control) and rivaroxaban-treated (intervention). Patients were clinically assessed for re-thrombosis, re-admission, bleeding, and mortality in the first, third, and sixth months after surgery.
RESULTS: There was no significant difference in the occurrence of thrombosis between the two groups within the first, third-, and sixth-months post-surgery (p=0.52, 1, 0.38 respectively). Moreover, the mortality rate (p=0.9), bleeding rate (p=0.06), and re-admission rate (p=0.15) showed no significant differences between the two groups.
CONCLUSION: Rivaroxaban may be as effective as warfarin in treating CTEPH patients after endarterectomy in the short term and can be used as an anticoagulant in these patients. However, studies with long-term follow-ups are needed to consolidate the strategy of treating these patients with rivaroxaban.
| Errataetall: |
CommentIn: Rev Port Cardiol. 2023 Feb;42(2):145-147. - PMID 36526131 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:42 |
|---|---|
| Enthalten in: |
Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology - 42(2023), 2 vom: 20. Feb., Seite 139-144 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Barati, Saghar [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 13.02.2023 Date Revised 22.02.2023 published: Print-Electronic CommentIn: Rev Port Cardiol. 2023 Feb;42(2):145-147. - PMID 36526131 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.repc.2021.09.023 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM347439020 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM347439020 | ||
| 003 | DE-627 | ||
| 005 | 20231226033827.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.repc.2021.09.023 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1158.xml |
| 035 | |a (DE-627)NLM347439020 | ||
| 035 | |a (NLM)36228832 | ||
| 035 | |a (PII)S0870-2551(22)00458-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Barati, Saghar |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Evaluating the efficacy and safety of rivaroxaban as a warfarin alternative in chronic thromboembolic pulmonary hypertension patients undergoing pulmonary endarterectomy |b A randomized clinical trial |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.02.2023 | ||
| 500 | |a Date Revised 22.02.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Rev Port Cardiol. 2023 Feb;42(2):145-147. - PMID 36526131 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Sociedade Portuguesa de Cardiologia. Publicado por Elsevier España, S.L.U. All rights reserved. | ||
| 520 | |a BACKGROUND AND AIM: Chronic thromboembolic pulmonary hypertension (CTEPH) is caused by the obstruction of the main pulmonary artery due to thrombosis and vascular remodeling. Regarding the need for anticoagulant therapy in CTEPH patients, this study aimed to compare rivaroxaban with warfarin in terms of its efficacy and safety in patients undergoing endarterectomy surgery | ||
| 520 | |a METHODS: The study was a parallel clinical trial in patients who underwent endarterectomy following CTEPH. A total of 96 patients were randomly selected and assigned to two groups: warfarin-treated (control) and rivaroxaban-treated (intervention). Patients were clinically assessed for re-thrombosis, re-admission, bleeding, and mortality in the first, third, and sixth months after surgery | ||
| 520 | |a RESULTS: There was no significant difference in the occurrence of thrombosis between the two groups within the first, third-, and sixth-months post-surgery (p=0.52, 1, 0.38 respectively). Moreover, the mortality rate (p=0.9), bleeding rate (p=0.06), and re-admission rate (p=0.15) showed no significant differences between the two groups | ||
| 520 | |a CONCLUSION: Rivaroxaban may be as effective as warfarin in treating CTEPH patients after endarterectomy in the short term and can be used as an anticoagulant in these patients. However, studies with long-term follow-ups are needed to consolidate the strategy of treating these patients with rivaroxaban | ||
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Chronic thromboembolic pulmonary hypertension | |
| 650 | 4 | |a Cirurgia | |
| 650 | 4 | |a Endarterectomia | |
| 650 | 4 | |a Endarterectomy | |
| 650 | 4 | |a Hipertensão pulmonar tromboembólica crónica | |
| 650 | 4 | |a Rivaroxaban | |
| 650 | 4 | |a Rivaroxabano | |
| 650 | 4 | |a Surgery | |
| 650 | 4 | |a Varfarina | |
| 650 | 4 | |a Warfarin | |
| 650 | 7 | |a Warfarin |2 NLM | |
| 650 | 7 | |a 5Q7ZVV76EI |2 NLM | |
| 650 | 7 | |a Rivaroxaban |2 NLM | |
| 650 | 7 | |a 9NDF7JZ4M3 |2 NLM | |
| 650 | 7 | |a Anticoagulants |2 NLM | |
| 700 | 1 | |a Amini, Hossein |e verfasserin |4 aut | |
| 700 | 1 | |a Ahmadi, Zargham Hossein |e verfasserin |4 aut | |
| 700 | 1 | |a Dastan, Alireza |e verfasserin |4 aut | |
| 700 | 1 | |a Sharif Kashani, Babak |e verfasserin |4 aut | |
| 700 | 1 | |a Eskandari, Raha |e verfasserin |4 aut | |
| 700 | 1 | |a Dastan, Farzaneh |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology |d 1992 |g 42(2023), 2 vom: 20. Feb., Seite 139-144 |w (DE-627)NLM012666386 |x 0870-2551 |7 nnns |
| 773 | 1 | 8 | |g volume:42 |g year:2023 |g number:2 |g day:20 |g month:02 |g pages:139-144 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.repc.2021.09.023 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 42 |j 2023 |e 2 |b 20 |c 02 |h 139-144 | ||